BridgeBio Pharma, Inc. — Form 8-K
Filed August 10, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 68/100
What the filing says
BridgeBio reported Q2 2026 total revenues of $243.7M (primarily $222.4M Attruby net product revenue, up 111% YoY). All three pipeline NDAs now under FDA Priority Review: BBP-418 for LGMD2I/R9 (PDUFA Nov 27, 2026), encaleret for ADH1 (PDUFA May 8, 2027), oral infigratinib for achondroplasia (NDA submitted, U.S. launch expected mid-2027). On July 1, 2026, BridgeBio closed $1 billion preferred equity financing led by Sixth Street and HealthCare Royalty. Cash position: $720.2M as of June 30, 2026. Net loss: $152.2M for Q2 2026 vs. $181.9M in Q2 2025.
Why this rating
Three simultaneous late-stage regulatory catalysts + transformational $1B financing + strong Attruby revenue growth materially advance launch execution. Relative to $7.3B market cap, this is significant but not business-changing alone.
See more from August 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.